reported that suppression of TGF-β signaling with antifibrotic drugs can significantly enhance the efficacy of nanoparticles with various sizes by reducing the ECM, decreasing interstitial fluid pressure, and improving tumor perfusion [178]. The gene discussed is TGFB1; the disease is neoplasm.